Chimerix Announces First Quarter Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Chimerix (CHMX) PT Lifted to $50 at Brean Capital
May 11, 2015 12:37 PM EDTBrean Capital analyst Jonathan Aschoff reiterated a Buy rating and boosted his price target on Chimerix (NASDAQ: CMRX) to $50.00 (from $45.00), saying Brinci has broad utility.
Aschoff commented, "The Phase 3 SUPPRESS trial with brincidofovir for the prevention of cytomegalovirus (CMV) in hematopoietic cell transplant patients is nearly 95% enrolled, and we expect it to be fully enrolled (n=450) in the summer of 2015 and read out pivotal... More
Chimerix (CMRX) Tops Q1 EPS by 3c
May 11, 2015 7:31 AM EDTChimerix (NASDAQ: CMRX) reported Q1 EPS of ($0.54), $0.03 better than the analyst estimate of ($0.57). Revenue for the quarter came in at $1.2 million versus the consensus estimate of $1.19 million.
For earnings history and earnings-related data on Chimerix (CMRX) click here.
... More